XML 48 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Note 4 - Income Taxes - Component of Deferred Tax Assets (Details) - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Stock option expense $ 689,600 $ 275,000
NOL carryforward 7,080,600 5,214,200
Research and development credits 1,656,500 1,656,500
Unrealized gain from investment in Alphazyme (69,800) 0
Other 7,900 4,400
Deferred tax asset, net of deferred tax liabilities 9,364,800 7,150,100
Valuation allowance (9,364,800) (7,150,100)
Net deferred tax asset $ 0 $ 0